Research in Israel finds Pfizer vaccine effective
Sheba Medical Center s Prof. Gili Regev found encouraging results in the 300 people examined that have had their first Covid-19 vaccine jab.
New research in Israel has provided real time insights into the efficacy of the Pfizer Covid-19 vaccine on those who have already been inoculated. Israel has already vaccinated more than 1.5 million people with the Pfizer vaccine including more than half of the population over 60. This is easily the largest proportion of the population and more in absolute numbers than most countries in the world. The UK for example has only vaccinated 1.3 million people, even though it began its vaccination drive two weeks before Israel. So all eyes are now focused on Israel to see if the vaccination can vanquish to virus.
Expanded phase II trial of Israel’s BriLife COVID-19 vaccine gets underway
The development of a “blue-and-white” vaccine is of strategic value, says Israeli President Reuven Rivlin.
Israeli President Reuven Rivlin (left) meets the first person to receive Israel s Brilife COVID-19 vaccine, as part of the expanded phase II trials, at Barzilai Medical Center in Ashkelon, on Jan 5, 2021. Photo: Amos Ben-Gershom/GPO.
Spread the word.
(January 6, 2021 / JNS) Israeli President Reuven Rivlin was on hand at the Barzilai Medical Center in Ashkelon on Tuesday to meet with the first person to receive Israel’s BriLife COVID-19 vaccine as part of its expanded phase II trial.
Jan 6, 2021
While Israel has already vaccinated 1.5 million people with Pfizer’s BioNTech formula, the locally developed vaccine entered phase two of its clinical trials.
By JNS
Israeli President Reuven Rivlin was on hand at the Barzilai Medical Center in Ashkelon on Tuesday to meet with the first person to receive Israel’s BriLife COVID-19 vaccine as part of its expanded phase II trial.
While Israel is already in the midst of a nationwide vaccination campaign, having administered the first dose of Pfizer’s BioNTech vaccine to nearly 1.5 million Israelis in the past two weeks and with millions of doses of Moderna’s vaccine on the way Rivlin stressed the importance of the Israel Institute for Biological Research’s locally developed vaccine.
Taburit wins Sheba cord blood bank tender
Taburit founded Sheba Medical Center s umbilical cord private blood bank after pioneering the field, and has been operating the blood bank since.
Taburit, which operates the cord blood bank at Sheba Medical Center at Tel Hashomer in Israel, has won the tender to operate the bank for an additional 10 years. Taburit, which founded the private umbilical cord blood bank at Sheba Medical Center, was the pioneer in the field 15 years ago, and has operated the hospital s blood bank since then. After several other companies withdrew from the sector, Taburit and Ta Lachaim (Medifreeze) are now the only two private cord blood bank operators in hospitals in Israel. Both companies competed for the tender, while Taburit ultimately won, while Ta Lechaim was disqualified after not agreeing to meet the terms of the tender.
Israeli ventilation system could give COVID-19 the smart treatment
The coronavirus ward of the Kaplan Medical Center in Rehovot, on Dec. 11, 2020.
(Israel Hayom via JNS) - An Israeli startup s groundbreaking innovation may provide a much-needed remedy to the shortage of ventilators and the overwhelming of staff in COVID-19 wards. Yehonatan Medical, in collaboration with Professor Ori Efrati, director of the Pediatric Pulmonary Unit at the Sheba Medical Center at Tel HaShomer, devised a state-of-the-art, first-of-its-kind ventilation system that can treat between three and five patients simultaneously. That means more patients treated by fewer ICU staff, the company said in a statement.